GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (STU:TPM0) » Definitions » E10

Tonix Pharmaceuticals Holding (STU:TPM0) E10 : €-127,027,000.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Tonix Pharmaceuticals Holding E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Tonix Pharmaceuticals Holding's adjusted earnings per share data for the three months ended in Mar. 2024 was €-5.299. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-127,027,000.00 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 26.60% per year. During the past 5 years, the average E10 Growth Rate was 23.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Tonix Pharmaceuticals Holding was 27.50% per year. The lowest was 10.50% per year. And the median was 22.15% per year.

As of today (2024-06-08), Tonix Pharmaceuticals Holding's current stock price is €90.24. Tonix Pharmaceuticals Holding's E10 for the quarter that ended in Mar. 2024 was €-127,027,000.00. Tonix Pharmaceuticals Holding's Shiller PE Ratio of today is .


Tonix Pharmaceuticals Holding E10 Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding E10 Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7,366,510.00 -6,505,360.00 -7,647,320.00 -7,206,910.00 -62,270,000.00

Tonix Pharmaceuticals Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8,446,440.00 -16,694,200.00 -48,735,400.00 -62,270,000.00 -127,027,000.00

Competitive Comparison of Tonix Pharmaceuticals Holding's E10

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tonix Pharmaceuticals Holding's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's Shiller PE Ratio falls into.



Tonix Pharmaceuticals Holding E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tonix Pharmaceuticals Holding's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-5.299/131.7762*131.7762
=-5.299

Current CPI (Mar. 2024) = 131.7762.

Tonix Pharmaceuticals Holding Quarterly Data

per share eps CPI Adj_EPS
201406 -4,448,384.000 100.560 -5,829,296.483
201409 -5,757,144.000 100.428 -7,554,228.602
201412 -7,290,079.000 99.070 -9,696,798.399
201503 -4,472,622.000 99.621 -5,916,268.052
201506 -5,240,416.500 100.684 -6,858,714.976
201509 -5,902,875.000 100.392 -7,748,249.967
201512 -6,132,240.000 99.792 -8,097,643.555
201603 -6,275,224.000 100.470 -8,230,535.291
201606 -2,909,116.300 101.688 -3,769,883.510
201609 -1,687,999.500 101.861 -2,183,742.156
201612 -1,182,156.000 101.863 -1,529,313.728
201703 -789,140.000 102.862 -1,010,962.924
201706 -386,745.050 103.349 -493,122.756
201709 -441,314.000 104.136 -558,451.499
201712 -386,798.750 104.011 -490,052.210
201803 -468,690.687 105.290 -586,594.843
201806 -400,805.736 106.317 -496,785.615
201809 -293,469.366 106.507 -363,097.137
201812 -190,813.320 105.998 -237,218.419
201903 -58,065.293 107.251 -71,343.478
201906 -52,206.062 108.070 -63,658.261
201909 -28,930.514 108.329 -35,192.230
201912 -7,549.065 108.420 -9,175.301
202003 -2,143.040 108.902 -2,593.184
202006 -1,307.136 108.767 -1,583.651
202009 -489.024 109.815 -586.821
202012 -526.080 109.897 -630.817
202103 -376.320 111.754 -443.741
202106 -373.500 114.631 -429.362
202109 -272.000 115.734 -309.702
202112 -396.480 117.630 -444.163
202203 -292.376 121.301 -317.625
202206 -231.278 125.017 -243.783
202209 -137.037 125.227 -144.204
202212 -105.728 125.222 -111.262
202303 -95.940 127.348 -99.276
202306 -79.156 128.729 -81.030
202309 -54.871 129.860 -55.681
202312 -13.678 129.419 -13.927
202403 -5.299 131.776 -5.299

Add all the adjusted EPS together and divide 10 will get our e10.


Tonix Pharmaceuticals Holding  (STU:TPM0) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Tonix Pharmaceuticals Holding E10 Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Tonix Pharmaceuticals Holding (STU:TPM0) Business Description

Traded in Other Exchanges
Address
26 Main Street, Suite 101, Chatham, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.

Tonix Pharmaceuticals Holding (STU:TPM0) Headlines

No Headlines